Is early access the answer to MFN?reframing EU launch strategy in a world of international reference pricing pressure

The re-emergence of Most Favoured Nation (MFN) style pricing policies and the broader political momentum behind international reference pricing has re-ignited a structural question for global biopharma:

Does launching in Europe now carry disproportionate global pricing risk?

For US-anchored manufacturers in particular, the concern is clear. If ex-US net prices cascade into US negotiations through IRA-linked discussions, reference baskets, or commercial contracting logic, then early EU pricing decisions cease to be local tactics. They become global anchors.

Against this backdrop, Early Access Programmes (EAPs) are increasingly discussed as a strategic hedge. The implicit thesis is simple

If a product can be supplied pre-launch under controlled, non-commercial frameworks, can this mitigate reference pricing exposure while maintaining clinical presence?

It is an attractive proposition. But it requires precision.

Understanding the MFN Overlay

The MFN mechanisms whether formally legislated or informally operationalised through payer benchmarking function by importing external price signals into domestic negotiations. The risk is not theoretical.

European markets operate with transparent list prices, structured HTA processes, and published reimbursement decisions. Even where confidential discounts exist, the list price can become a reference point.

For US manufacturers, a number of structural tensions now exist:

1. EU list prices can anchor global perception Even if net prices differ materially, list prices can influence negotiation psychology and policy debates.

2. Launch sequence has become a strategic lever The traditional “US first, EU follow” model is being reassessed, particularly in rare disease and specialty categories.

3. Price erosion is hard to reverse Once a low reference point is established, upward correction is politically and commercially difficult.

   
   

The result is strategic hesitation. Some companies delay EU launches. Others compress timelines. Many quietly reassess their early access posture.

What EAP actually does and does not solve?

Early Access Programmes whether Named Patient, Cohort, Compassionate Use, AP1/AP2 (France), 648/326 (Italy), §73(3) AMG (Germany), or MHRA frameworks in the UK allow supply of unlicensed or pre-reimbursed medicines under controlled conditions.

• Providing treatment where unmet need exists

• Generating real-world evidence ahead of HTA submission

• Building clinical familiarity pre-launch

However, EAP is not a pricing vacuum. It is a regulated supply mechanism. That distinction matters.

What EAP can achieve strategically?

1. Time decoupling EAP can separate patient access from formal price establishment. This creates optionality particularly where US pricing exposure is sensitive.

2. Evidence acceleration In markets like France or Italy, structured early access pathways can generate data that materially strengthens HTA positioning. A stronger HTA outcome may support firmer list pricing.

3. Market conditioning without formal reimbursement Clinician sequencing patterns, switching triggers, and operational bottlenecks become visible before commercial launch.

4. Controlled patient volume Cohort programmes can regulate exposure while maintaining ethical supply.

What EAP Does Not Do?

• It does not permanently shield global pricing.

• It does not eliminate future list price disclosure.

• It does not avoid eventual HTA confrontation.

• It does not automatically prevent reference pricing capture once a list price is established.

  
  

If EAP is used purely as a delay tactic, it becomes a holding pattern — not a strategy.

The real strategic question?

The correct question is not:

“Is EAP the answer to MFN?”

The correct question is:

“How can early access be integrated into a sequencing strategy that optimises global pricing durability?”

This is where nuance becomes essential.

Several strategic archetypes are emerging

Across US and global biotech portfolios, four patterns are emerging:

The defensive delay model

EU launch is postponed. EAP supplies minimal patient numbers. Formal pricing is deferred until US negotiations stabilise.

Risk: Clinical momentum stalls. Competitors advance.

The evidence-first model

EAP is used aggressively to generate RWE that supports premium positioning at formal launch.

Benefit: HTA robustness increases.Risk: Execution complexity.

The segmented indication strategy

High-value subpopulations are supplied under early access while broader label expansion is delayed.

Benefit: Price integrity preserved in narrow cohorts.Risk: Ethical and operational scrutiny.

The anchor market control model

Manufacturers carefully select first EU launch markets based on reference basket impact and pricing transparency. EAP becomes a bridge not an endpoint.

The operational reality

Early Access Programmes introduce material complexity:

• Pharmacovigilance obligations remain intact.

• Importation and unlicensed supply compliance is market specific.

• Manufacturer liability persists.

• Distribution models must be robust.

• Data capture must be structured from day one.

  
  

Poorly designed EAP frameworks create downstream regulatory and HTA vulnerabilities.

This is not theoretical. We have seen:

• Inadequate data collection undermining future submissions.

• Inconsistent pricing logic between early access and launch.

• Distribution partners misaligned with long-term commercial intent.

  
  

EAP without operational discipline amplifies risk rather than reducing it.

Where EAP can truly be powerful?

Used correctly, early access becomes a strategic stress test, revealing…

• Real clinician behaviour (not advisory board theory)

• Switching dynamics

• Persistence rates

• Safety signals in routine practice

• Operational friction in supply chain

  
  

In rare disease and specialty markets, this intelligence is frequently more valuable than incremental clinical endpoints.MFN risk is fundamentally about price visibility.EAP strength is fundamentally about value visibility.The strategic opportunity lies in converting early access evidence into a defensible value narrative that supports durable pricing later.

A more sophisticated view

EAP is not the answer to MFN.But it is a lever within a broader launch architecture that must now include:

• Reference basket modelling

• Sequencing logic by jurisdiction

• Net-to-list sensitivity analysis

• US negotiation timing alignment

• Real-world evidence planning integrated pre-launch

• Distribution partner selection aligned to long-term model

The companies that will navigate MFN pressure most effectively are not those who retreat from Europe. They are those who integrate early access into a deliberate, sequenced, data-driven commercialisation plan.

Conclusion

If MFN increases the cost of price visibility, then early access strategy must increase the strength of value visibility. Early Access Programmes are not a shield.They are a staging ground.Used tactically, they buy time.Used strategically, they build leverage.The difference lies in design.For manufacturers reassessing EU launch sequencing in the current policy climate, the question is no longer whether to engage with early access but how to architect it in a way that protects global pricing durability while accelerating clinical adoption.That is where strategy moves from defensive to intentional.